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488 The Journal of Thoracic and CardioIn this issue of the Journal, Yun and colleagues1 from Kaiser PermanenteMedical Center in Los Angeles and Providence Health System present uswith an excellent prospective randomized study comparing the midtermangiographic patency results between open saphenous vein harvesting andendoscopic vein harvesting (EVH). The study design is superb, the statis-tical analyses are impeccable, and the discussion is insightful and erudite.
However, the clinical outcomes presented therein should have us all turning our
heads and thinking further about how we do that thing we do on an almost daily
basis: namely, coronary artery bypass surgery.
But which way should our heads be turning? As with many great articles, this
one answers several important questions with regard to the efficacy and safety
of EVH, but for me (and I suspect for many others out there), it raises a plethora
of philosophical questions about the nature of that thing we do that have been
left unanswered. Thus in my view these results, the questions they answer, and
the contemplative ones they concomitantly raise can be summarized (with all
due respect to Clint Eastwood, Lee Van Cleef, and Eli Wallach) as “The Good,
The Bad, and The Ugly,” with a new character thrown into the mix: “The
Excellent.”
The Good
EVH techniques are just as good as open harvesting techniques in terms of bypass
graft patency. When evaluated by means of angiography at 6-month follow-up, there
were no differences between the 2 techniques in overall patency, nor were there
differences in the incidence of stenoses of patent vein grafts. Thus one can conclude
that the use of EVH does not compromise midterm (6-month) vein graft patency.
EVH is good for the patient. The Yun study shows that EVH independently
reduces leg wound complications by 67% compared with the open harvesting
techniques. Furthermore, the leg wound complications that occurred were relatively
minor compared with those that occurred with the open technique. In this respect
EVH is absolutely, positively better than open harvesting. These are not new
findings, but they nicely corroborate those already published and referenced by the
authors.
EVH is good for diabetic patients. According to The Society for Thoracic
Surgeons (STS) database, diabetic patients make up 29% of the coronary artery
bypass grafting (CABG) population in this country, and the incidence is steadily
increasing. In the Yun study diabetes was “surprisingly” found not to predispose to
leg wound complications. This is not surprising in the least because all patients in
this study were maintained on an insulin infusion protocol that strictly controlled
blood glucose at less than 150 mg/dL. This is well below the 180 mg/dL (10 mmol)
threshold of nonenzymatic glycation, which is the primary cause of impaired







Limmunity in these patients. Thus these data show that strict
glucose control is also good for all patients. What else
would you expect me to say?
In our practice in Portland, 98% of saphenous vein grafts
are harvested by means of EVH techniques. In the past,
when patients used to come into our office for follow-up
after CABG with open harvesting, they invariably had jus-
tifiable complaints about their leg incisions, such as persis-
tent pain, poor healing, tightness, weeping, and ugly scars.
One could hardly get them to talk about anything else. Now,
with the ubiquitous use of EVH in our practice, they have to
be directly queried about potential problems at their harvest
site: “How’s your leg doing?” “Why? What’s wrong with
my leg?!” routinely comes the response.
The Excellent
On the basis of the article by Yun and colleagues and others
referenced therein, it should be obvious to the astute reader
that EVH is a significant advance in the application of that
thing we do because it diminishes the negative effect of
traditional venous CABG without altering the midterm ef-
ficacy of the operation. How and why has this tremendous
advance come about some 30 years after the inception of the
operation itself? Was it enabled by a deluge of venture
capital money looking for a place to proliferate, like leav-
ened bread under a warm towel? Maybe. Were we shamed
into it by the general and obstetric surgeons who were
already minimizing the approaches to the things they do on
a daily basis? Probably not: we’re cardiothoracic surgeons,
for God’s sake! Was this an intuitive advance that we as
cardiothoracic surgeons had to have? Never.
Rather, I submit to you that this incredible advance
has come about and been successfully proliferated
throughout our profession solely because of the dedica-
tion and perseverance of our right-hand men and women,
our comrades-at-arms: the cardiovascular physician’s as-
sistants (CVPAs). These men and women are the excel-
lent part of this story. They alone have brought about this
advance in the safe application of our craft and have
allowed us to claim another small victory in that thing we
do. Yes, there have been surgeons involved along the
way—Fogarty, Moon, Perrault, Puskas— but these are a
few who have championed the cause to the masses of
surgeons; there are fewer still who have taken the time to
perform EVH themselves on a routine basis. And, yes, it
often required some prodding and patience on our part,
but for the most part, the widespread application of EVH
came about because of the excellence of determination
and steadfast will of the CVPAs. They have allowed us to
take that thing we do to new places for we would not have
had the time or the perseverance to go there ourselves.
While we were concentrating on the sexy subjects of
off-pump coronary artery bypass, arterial grafting, robot-
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assist devices, artificial hearts, and the like, these excel-
lent young men and women took our gold standard op-
eration and kicked it up a notch.
To all of our excellent CVPAs, from all of us surgeons
and especially from all of our patients, a warm, heart-felt,
and well-deserved thank you is in order. You make that
thing we do easier for us, better for the health care system,
and safer for our patients.
The Bad
Having said all that, I was saddened not to see a single
CVPA name in the authorship list or even acknowledged in
the Yun article. All too often the real heroes in a story are
overlooked as technology rapidly advances and victory is
declared by industry leaders and the captains of our various
ships. To me, these are bad precedents that must change to
continue to stimulate teamwork and growth in our profes-
sion and attract, retain, and encourage excellence in our
CVPAs.
But “The Bad” comes in other flavors from this article as
well. Although the occlusion and restenosis rates are equiv-
alent, they are anything but good. At 6 months there is a
20% overall occlusion rate and a 31.5% rate of occlusion or
restenosis of greater than 50%.
“You have got to be kidding me,” I thought. “This is
definitely bad. But wait, our results couldn’t be as bad as
these. Those men and women must not be ‘as good’ as me
and my partners. We have great results here.”
Unfortunately, none of us really know what our individ-
ual patency and restenosis rates are for venous CABG.
Most, if not all of us, believe we are great technical sur-
geons: it has to be so for us to emotionally survive in this
highly demanding profession. We believe our bypasses last
longer than those of others who have time to publish their
results; we believe we can graft 1-mm coronary vessels
perfectly and that they will last for years to come. Reality
dictates otherwise.
This cardiovascular surgical “ostrich phenomenon” is
another interesting component of this story. It does not
always happen—in fact, I think it is becoming more rare—
but when it does, it is really bad for the surgeon and his or
her patients. Fortunately, through weeks, months, and years
of surgical morbidity and mortality conferences, most sur-
geons come to realize we cannot improve on our failures
unless we first accept our own shortcomings and then seek
solutions.
This is where the current article lets its inquisitive read-
ers down because it offers us few, if any, clinically relevant
clinical clues as to how we could improve on these percep-
tively poor results. The only independent predictors of vein
graft patency were congestive heart failure, ultrasonically
measured vein graft flow, and grafting to the diagonal





Lterritory, none of which are modifiable at the time of the
operation. We certainly are not going to skip a graft to a
diagonal artery because it might go down, nor are we going
to ignore needed grafts in patients with congestive failure;
few, if any, would redo a graft with slightly lower flows
after completion.
However, some suggestive clues do exist. When flow
was removed from the equation, the authors found that the
severity of distal coronary disease became a significant
predictor of occlusion. In addition, diagonal grafting and
decreased flow might be surrogate variables for smaller
target vessels and poor coronary runoff. Larger vein grafts
also appear to be bad in terms of patency. Unfortunately, the
authors give us no information on specific target and graft
size and quality with which we could modify the daily
practice of that thing we do. How large is too large? How
small is too small? Should we be using calf veins? What
about the lay of the graft at completion? This was not
assessed as a variable in this study. A more accurate assess-
ment of the quality of the vein graft—thick or thin walled,
multiple branches, size changes, varicosities, and such—
would have been clinically helpful. Thus it would have also
been helpful and highly important to see univariate analyses
of coronary size, vein graft size, and quality with respect to
patency.
The Ugly
The importance of these unpublished relationships becomes
evident when we examine the potential market effect of
“The Ugly”; that is, the potential market effect of these data
in the hands of the enterprising, entrepreneurial, well-
funded percutaneous interventional drug-eluting stent
(DES) marketeers. DESs have an established 6-month re-
stenosis rate of 6% to 9%. Obviously, even using old math,
this appears to be way better than the 31% reported herein.
On the surface, an easy argument could be made to the lay
public that DESs are better than CABG vein grafts, and I am
sure that will occur if it has not already. What must be
pointed out is that a graft to a 1.25-mm artery distal in a
diseased coronary tree could not and should not be expected
to have the same patency outcomes as a DES to a 3-mm
proximal arterial stent. Furthermore, because more and
more DESs are being placed in patients with large multives-
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and diffusely diseased vessels, which we are asked to graft.
Thus our success rates in terms of patency will, by neces-
sity, go down.
So what is a surgeon to do? The answer should be
intuitive; in fact, it must be intuitive because it cannot be
explicitly derived from these data. It is anything and every-
thing possible to help the patient. What is most important to
the patient? Is it graft patency? No. Is it an incision on their
chest versus a stick in the groin? To some, maybe. These are
the obtuse marketing angles that will be used by the percu-
taneous marketeers to advance their trade and raise the
value of their stock: laudable goals in the business world.
But what is truly of ultimate importance in the real world
of the patient is survival, most specifically long-term sur-
vival. This has been the goal of cardiac surgery since its
inception. It is the basic tenet of our profession and the goal
on which we as surgeons should refocus and of which
patients should be made aware. Coronary bypass grafting
produces better 5-year survival rates than multivessel stent-
ing, multiple arterial grafting improves survival compared
with multivein grafting, complete revascularization im-
proves survival compared with incomplete revasculariza-
tion, glucose control improves survival in diabetic patients,
and there are more.
We, as individual surgeons, can and must do our part by
making patients and primary care physicians aware of the
survival data, increasing our use of multiple arterial graft-
ing, completely revascularizing all our patients whenever
possible, using transmyocaridal revascularization to im-
prove the completeness of revascularization in patients with
suboptimal targets or grafts, incorporating insulin infusion
protocols, and, yes, using endoscopically harvested vein
grafts when veins must be used. If we embrace internal
changes that focus on and enhance our basic goal, external
changes that are not focused on this ultimate goal have no
chance of making that thing we do obsolete.
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